Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

GLP-1 agonists are a class of medications that mimic the action of the hormone GLP-1 (glucagon-like peptide-1), which is ...

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry ...

Jan. 4, 2024 — A new study demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1 ... You might be familiar with the drug’s digestive side effects, like nausea and ...